Switch theme
Sign up to access all valuation multiples
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
2002
499
LTM Revenue $567M
LTM EBITDA $57.2M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amicus Therapeutics has a last 12-month revenue (LTM) of $567M and a last 12-month EBITDA of $57.2M.
In the most recent fiscal year, Amicus Therapeutics achieved revenue of $528M and an EBITDA of $29.4M.
Amicus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amicus Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $567M | XXX | $528M | XXX | XXX | XXX |
| Gross Profit | $501M | XXX | $475M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $57.2M | XXX | $29.4M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 6% | XXX | XXX | XXX |
| EBIT | $32.5M | XXX | $34.1M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | -$44.3M | XXX | -$56.1M | XXX | XXX | XXX |
| Net Margin | -8% | XXX | -11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $176M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Amicus Therapeutics's stock price is $6.
Amicus Therapeutics has current market cap of $1.9B, and EV of $2.1B.
See Amicus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $1.9B | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Amicus Therapeutics has market cap of $1.9B and EV of $2.1B.
Amicus Therapeutics's trades at 3.9x EV/Revenue multiple, and 70.1x EV/EBITDA.
Equity research analysts estimate Amicus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amicus Therapeutics has a P/E ratio of -42.2x.
See valuation multiples for Amicus Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 36.0x | XXX | 70.1x | XXX | XXX | XXX |
| EV/EBIT | 63.3x | XXX | 60.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -42.2x | XXX | -33.3x | XXX | XXX | XXX |
| EV/FCF | -129.4x | XXX | -55.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmicus Therapeutics's last 12 month revenue growth is 20%
Amicus Therapeutics's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.
Amicus Therapeutics's rule of 40 is -3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Amicus Therapeutics's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Amicus Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 145% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amicus Therapeutics acquired XXX companies to date.
Last acquisition by Amicus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Amicus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Amicus Therapeutics founded? | Amicus Therapeutics was founded in 2002. |
| Where is Amicus Therapeutics headquartered? | Amicus Therapeutics is headquartered in United States of America. |
| How many employees does Amicus Therapeutics have? | As of today, Amicus Therapeutics has 499 employees. |
| Who is the CEO of Amicus Therapeutics? | Amicus Therapeutics's CEO is Mr. Bradley L. Campbell. |
| Is Amicus Therapeutics publicy listed? | Yes, Amicus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Amicus Therapeutics? | Amicus Therapeutics trades under FOLD ticker. |
| When did Amicus Therapeutics go public? | Amicus Therapeutics went public in 2007. |
| Who are competitors of Amicus Therapeutics? | Similar companies to Amicus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Amicus Therapeutics? | Amicus Therapeutics's current market cap is $1.9B |
| What is the current revenue of Amicus Therapeutics? | Amicus Therapeutics's last 12 months revenue is $567M. |
| What is the current revenue growth of Amicus Therapeutics? | Amicus Therapeutics revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Amicus Therapeutics? | Current revenue multiple of Amicus Therapeutics is 3.6x. |
| Is Amicus Therapeutics profitable? | Yes, Amicus Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Amicus Therapeutics? | Amicus Therapeutics's last 12 months EBITDA is $57.2M. |
| What is Amicus Therapeutics's EBITDA margin? | Amicus Therapeutics's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Amicus Therapeutics? | Current EBITDA multiple of Amicus Therapeutics is 36.0x. |
| What is the current FCF of Amicus Therapeutics? | Amicus Therapeutics's last 12 months FCF is -$15.9M. |
| What is Amicus Therapeutics's FCF margin? | Amicus Therapeutics's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of Amicus Therapeutics? | Current FCF multiple of Amicus Therapeutics is -129.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
